The story appears on

Page A6

November 23, 2017

GET this page in PDF

Free for subscribers

View shopping cart

Related News

HomeNation

2nd-generation HPV vaccine approved

A second-generation HPV vaccine has been approved by China Food and Drug Administration for clinical testing, the developer said yesterday.

It is the world鈥檚 second second-generation human papilloma virus (HPV) vaccine to reach the clinical test stage, following one developed by Merck, which also obtained permission for clinical testing in China.

The research is led by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases, based at Xiamen University in southeast China鈥檚 Fujian Province.

The vaccine will be produced in Xiamen, if approved.

Compared with the first-generation vaccine, the new one can protect against five more high-risk types of HPV and two more low-risk types. It is estimated it will be able to prevent about 90 percent of cervical cancers and genital warts.

Developers at Xiamen University said the vaccine uses more cost-effective coliform bacteria as the effective antigen, while foreign companies use yeast or insect cells, giving it an edge in the market.


 

Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

娌叕缃戝畨澶 31010602000204鍙

Email this to your friend